NIA Home > About NIA > National Advisory Council on Aging > Meeting Information
The FY 2001 appropriation provides for 1,269 research project grants at a funding level of $527,902,000. Within this amount, NIA will support 422 competing RPGs.
The significant funding increase in FY 2001 will permit continued growth of the NIA's research efforts, including expanded efforts in such areas as health disparities, Alzheimer's disease, cardiovascular disease, the genetics of aging, behavioral and social research, and studies of older cancer patients in clinical trials.
The appropriation provides increases for the Institute's centers and research and development contract programs. The increase in the career mechanism includes funding to strengthen new training mechanisms for clinical researchers. The salary cap for investigators is increased to $75,000.
The increase in the Intramural research mechanism will allow NIA's Gerontology Research Center to increase its program of research into congestive heart failure and other aspects of cardiovascular disease. GRC will also be able to expand its work in the areas of gene regulation, caloric restriction and mouse genomics. It will also permit funding of several initiatives related to minority health. The increased level of funding for Research Management and Support will be used to provide scientific oversight to assure integrity of applications funded, to develop research initiatives within the scientific community, and to improve information technology infrastructure in support of scientific staff.
The Clinton administration was required to submit a Fiscal Year 2002 President's Budget to Congress before leaving office. This will, however, be revised at a later date by the Bush Administration.
(Contact: Ms. Karyn Ross, FMISB, 301/496-9147)
H.R. 3514, Chimpanzee Health Improvement, Maintenance, and Protection Act On December 20, the President signed H.R. 3514 (P.L. 106-551), the Chimpanzee Health Improvement, Maintenance, and Protection Act. The bill initially passed the House on October 24 and the Senate on December 6, 2000. The law provides for a system of sanctuaries for chimpanzees that have been designated as being no longer needed in research conducted or supported by the U.S. Public Health Service.
H.R. 1795, National Institute of Biomedical Imaging and Bioengineering Establishment Act On December 29, the President signed H.R. 1795, the National Institute of Biomedical Imaging and Bioengineering Establishment Act. H.R. 1795 initially passed the House on September 27 and the Senate on December 15, 2000. The law creates the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health (NIH).
H.R 4365, Children's Health Act of 2000 On October 17, the President signed H.R. 4365 (P.L. 106-310), the Children's Health Act of 2000. The bill, which initially passed the House on May 9, 2000, and the Senate on September 22, 2000, contains provisions that would authorize Federal research into autism, Fragile X, juvenile arthritis, diabetes, asthma, hearing loss in infants, epilepsy, traumatic brain injuries, muscular dystrophy, childhood malignancies, birth defects and autoimmune diseases, loan repayment for pediatric researchers and pediatric research human subject protections. The law also requires NIH to issue a report on its activities regarding rare diseases in children, including Hutchinson-Guildford syndrome, which will require input from the NIA and other NIH Institutes and Centers.
H.R. 2498, Public Health Improvement Act On November 13, the President signed into law H.R. 2498, the Public Health Improvement Act (P.L. 106-505). This measure, which passed the House and Senate on October 27, 2000, contains ten separate bills, including H. R. 4015, the Alzheimer's Clinical Research and Training Awards Act of 2000. Under this new awards program, the NIA Director is authorized to make awards to enhance and promote the translation of new scientific knowledge into clinical practice related to the diagnosis, care and treatment of individuals with Alzheimer's disease. The new law stipulates that awards will be made to promising clinicians for research, study, and practice at centers of excellence in Alzheimer's disease research and treatment.
H.R. 782, Older Americans Act of 2000 On November 13, the President signed into law H.R. 782, the Older Americans Act of 2000 (P.L. 106-501), which passed the House on October 24, 2000, and the Senate on October 26, 2000. The legislation reauthorizes and amends the Older American's Act of 1965 and the Older Americans Act Amendments of 1987. A provision of H.R. 782 requires a White House Conference on Aging to be convened no later than December 31, 2005. The Conference is to be planned and conducted under the direction of the Secretary of Health and Human Services in cooperation with other federal agencies, including the Director of the National Institute on Aging.
S. 1880, Minority Health and Health Disparities Research Act of 2000 On November 22, the President signed S. 1880, the Minority Health and Health Disparities Research Act of 2000 (P.L. 106-525), which the Senate passed on October 26, 2000, and the House passed on October 31, 2000. Provisions of the Act establish in statute a National Center for Minority Health and Health Disparities at the NIH to coordinate health disparities research performed or supported by NIH; a grant program through the new Center to further biomedical and behavioral research education and training; an endowment program to facilitate minority and other health disparities research at centers of excellence; and a loan repayment program to train members of minority or other health disparities populations as biomedical research professionals.
NIH Publishes Final Guidelines for Stem Cell Research On August 25, the National Institutes of Health (NIH) published its final guidelines for research involving human pluripotent stem cells in the Federal Register. The guidelines detail the procedures to help ensure that NIH-funded human pluripotent stem cell research is conducted in an ethical and legal manner. (Also see the Initiatives section for information concerning the approval process for documenting compliance with these guidelines.)
Senate Hearing on Barriers to Hospice Care On September 18, the Senate Special Committee on Aging conducted a hearing on barriers to hospice care. Dr. Nicholas Christakis, an NIA grantee from the University of Chicago, testified about his research on this topic.
Capitol Hill Briefing/Exhibit on the Decade of Behavior On September 25, Dr. Robert Willis, an NIA grantee from the University of Michigan, participated in a briefing/exhibit on Capitol Hill organized by the American Psychological Association to launch the Decade of Behavior initiative. Dr. Willis and his colleagues presented information about the Health and Retirement Survey.
Presentation of Harvard Millennium Lecture On September 20, Dr. Richard Hodes, Director, National Institute on Aging (NIA), presented the Harvard Millennium Lecture. The title of his presentation was “ Progress and Promise in Basic and Translational Research on Aging.”
Meeting with Representative of Parkinson's Disease Community On September 28, Dr. Richard Hodes, Dr. Marcelle Morrison-Bogorad, Acting NIA Deputy Director, and other NIA staff members met with Mr. Jeffrey Martin, a representative of the Parkinson's disease community. Mr. Martin requested the meeting to discuss the NIH Five-Year Parkinson's Disease Research Agenda and NIA activities related to Parkinson's disease research.
Meeting with Ad Hoc Group for Medical Research Funding On October 3, representatives of the Ad Hoc Group for Medical Research Funding met with Dr. Richard Hodes to discuss ongoing and future NIA research activities.
Meeting with National Coalition for Osteoporosis and Related Bone Diseases On October 26, Dr. Richard Hodes met with representatives from the National Coalition for Osteoporosis and Related Bone Diseases to discuss relevant ongoing and future research and information-related activities.
Presentation to National Advisory Council for Complementary and Alternative Medicine On November 13, Dr. Richard Hodes spoke to the National Advisory Council for Complementary and Alternative Medicine, which advises the Director of the National Center for Complementary and Alternative Medicine. Dr. Hodes discussed relevant NIA activities and potential future complementary and alternative research opportunities.
Meeting with Progeria Research Foundation On November 17, Dr. Richard Hodes and Dr. Huber Warner, Associate Director, NIA Biology of Aging program, and other NIH officials, met with the representatives of the Progeria Research Foundation (PRF). PRF, which advocates for research on Hutchinson-Guilford syndrome, requested the meeting to discuss the status of scientific opportunities and potential research collaborations with the NIH.
Contact: Ms. Mary Jo Hoeksema, NIA Legislative Officer, (301) 496-0261
Dr. Mary Starke Harper, member of the National Advisory Council on Aging, was honored by the United Seniors Health Cooperative for her work in the field of aging and mental health. The citation reads, in part: "A nurse, clinical psychologist, professor, researcher, author, and public policy expert, she took the leadership in launching the discipline of geriatric psychiatry and charting the once unexplored terrain where behavioral health care and psychology meet. A passionate voice for better health care, medicine and public policy, she is a champion for older Americans."
Dr. Rebecca Fuldner joined the Biology of Aging Program (BAP) on November 19, 2000. She will administer and develop the Immunology portfolio in BAP and lead an initiative to develop screening methods for mouse mutants of import to the study of aging. Dr. Fuldner first joined the NIH as a Scientific Review Administrator at the National Center for Research Resources where she was responsible for review of Biomedical Technology, Centers of Biomedical Research Excellence (COBRE) and General Clinical Research Center (GCRC) applications. Prior to that she had experience as a Clinical Research Specialist at Technical Resources, Inc., a Patent Examiner at the U.S. Patent and Trademark Office, and as Associate Scientist and Project Leader at The Institute for Genomic Research (TIGR) of the Alzheimer's Disease Collaborative Group.
Ms. Linda Whipp, a capable veteran of the NIA Grants and Contracts Management Office (GCMO), accepted the position of Grants and Contracts Management Officer. Ms. Whipp most recently served as Deputy Grants Management Officer. She came to NIA in 1988 as a Budget Analyst. Before that, Ms. Whipp worked in the Center for Scientific Review.
Jean Richelsen joined the GCMO as a Grants Management Specialist in September 2000. The newest additions are Ms. Lesa McQueen, previously with BSR, and Ms. Grace Poe, previously with the National Heart, Lung, and Blood Institute (NHLBI).
Staff changes in the Behavioral and Social Research Program include the departure of Dr. Jared Jobe and Ms. Georgeanne Patmios. Dr. Jobe left the NIA to work at the NHLBI. Ms. Patmios accepted a position with the staff of the Office of Behavioral and Social Science Research (OBSSR) with Dr. Raynard Kington.
Dr. James Corrigan, former head of the NIA Office of Planning, Analysis, and Evaluation, left to join the staff at the National Cancer Institute.
Social Relationships and Risk of Cognitive Decline in the Elderly. The Behavioral and Social Research (BSR) Program sponsored this exploratory workshop, which was held on December 1, 2000, in Bethesda, Maryland. The lead speaker, Dr. Laura Fratiglioni, presented the noteworthy finding that while frequency of contact with children, relatives, and friends is predictive of the onset of dementia, degree of satisfaction with these relationships is even more important. The participants discussed a variety of issues, such as current gaps in our knowledge concerning various mechanisms that may be responsible for this association, including the possibility that prodromal cognitive decline may precipitate exclusion from existing social relationships. Additional topics discussed were issues in measuring social relationships (e.g., social density, types of social support, varieties of social participation and engagement) and the optimal timing of interventions. The workshop generated a number of useful recommendations for future research directions, including ways to unpack the construct of social engagement that would permit further headway toward pinning down the most crucial facets of interpersonal relationships which impact cognitive status downstream. (Contact: Dr. Daniel Berch, BSR, 301-496-3137)
The NIA Primate Models of Menopause Workshop was held on January 10, 2001, in Bethesda. The purposes of this advisory workshop were: (a) to review studies addressing the process of female reproductive aging in female non-human primates and the physiologic connections between that process and health problems or conditions associated with the menopause, and (b) to obtain recommendations from the advisory committee for future research initiatives and programmatic efforts by the NIA and other NIH Institutes or centers in furthering this research area. Final recommendations are still pending from this recent workshop. (Contact: Dr. Frank Bellino, BAP, 301-496-6402)
Cognitive and Emotional Aspects of Parkinson's Disease Working Group Meeting The Neuroscience and Neuropsychology of Aging (NNA) Program cosponsored an advisory working meeting on "Cognitive and Emotional Aspects of Parkinson's Disease" January 25 and 26. This workshop brought together NIH extramural and intramural scientists, with both basic and clinical expertise, in order to pinpoint new opportunities for research and treatment of the non-motor aspects of Parkinson's disease. Two Working Groups (I-Depression and Parkinson's Disease; II-Interactions and Overlap of Psychiatric and Cognitive Changes Associated with Parkinson's Disease and Alzheimer's Disease) were charged with assisting NINDS (National Institute of Neurological Disorders and Stroke), NIMH (National Institute of Mental Health), and NIA, in addressing the specific recommendation of the NIH Parkinson's Disease Coordinating Committee to focus on the non-motor symptoms of Parkinson's disease, such as the psychiatric and cognitive impairments. The Working Group members were asked to take a broad view in identifying and prioritizing unmet scientific needs and opportunities that are critical to the advancement of research on psychiatric and cognitive aspects of Parkinson's disease. (Contact: Dr. Judith Finkelstein, NNA, 301-496-9350)
Expert Panel on Doubly Labeled Water Methodology (Exploratory Workshop). The Geriatrics Program (GP) will convene an expert panel in Bethesda on February 6, 2001, to review the current doubly labeled water (DLW) protocols to identify potential ways of refining the DLW technique (e.g., use lower doses of 18O, altering the dosing schedule, etc.) for future studies of energy expenditure. The expertise represented in the composition of the expert panel will include biophysicists, nutrition, metabolism, and exercise physiologists. It is anticipated that a summary article of the panel's recommendation will be published. (Contact: Dr. Chhanda Dutta, GP, 301-435-3048)
Diabetes and Aging: From Basic Biology to Clinical Care What Are New Research Directions for Understanding Diabetes in Older Age This scientific conference, cosponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, the NIA, and the Diabetes Mellitus Interagency Coordinating Committee, will be held on February 12-13, 2001, in Bethesda, MD. (Contact: Dr. Reubin Andres, IRP, 410-558-8193)
The Biology of Aging Program plans an exploratory workshop in the area of Musculoskeletal Biology. This meeting is to be held in March 2001 and will include 5-7 experts in the areas of cartilage, bone, muscle and skin aging. The purpose of this exploratory workshop is to discuss the major advances and issues in this area and explore areas of overlap in issues of muscle, bone, and cartilage aging. (Contact: Dr. Jill Carrington, BAP, 301-496-6402)
Metabolic and Body Composition Influences of Aging and Disease Risk (Advisory Workshop). The Geriatrics Program is planning a workshop to explore potential metabolic mechanism(s)/factors that contribute to and/or underlie deleterious changes in body composition that can lead to metabolic disorders in old age. This workshop will be held in Bethesda, MD, in April-May 2001. The objectives of this workshop will be: (1) to review metabolic mechanisms/factors known to influence changes in body composition during sexual maturation and in old age, (2) to identify those factors influencing body composition during sexual maturation, which may be most relevant to changes in old age, and (3) to recommend future directions/experiments needed in this under explored area of aging research. It is anticipated that the information presented and the recommendations from this workshop will be published in a peer-reviewed journal. (Contact: Dr. Chhanda Dutta, GP, 301-435-3048)
Menopause and Women's Health: A Comprehensive Approach (Exploratory Workshop). The NIA (Geriatrics Program), the Office of Research on Women's Health, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases are co-sponsoring this workshop initiated by the Giovannie Lorenzini Foundation (Italy) and the National Heart, Lung, and Blood Institute. This workshop will be held on May 19-May 23, 2001, Washington, DC. Dr. Sherry Sherman will chair the session, “International Longitudinal Studies and the Menopause Transition.” The purpose of the workshop is to update physicians and other health care professionals on recent research in the field of women's health and menopause. The central message to be conveyed to the audience is that the growing understanding of estrogen action, including receptors, has been providing new insights not only into physiology and pathology but also into clinical application. (Contact: Dr. Sherry Sherman, GP, 301-435-3048)
NIA/NCI Cancer Centers Exploratory Workshop--“Exploring the Role of Cancer Centers to Integrate Aging and Cancer Research.” The NCI (National Cancer Institute) Cancer Centers Program supports major academic and research institutions throughout the United States to sustain broad based, coordinated, interdisciplinary programs in cancer research. The NCI Cancer Centers represent a potential network of institutions that could be mobilized to establish innovative programs to conduct research on cancer diagnosis and treatment in older patients. Inter-Institute studies and collaborations among investigators in oncology and geriatric medicine as well as the biology of aging and cancer could be promoted. This workshop will explore with senior cancer center representatives (i.e., center directors, individual researchers, science administrators, scientific program directors) the cancer center expertise and resources that could be brought together to conduct research on the aging/cancer interface. The focus is on human cancer. NIH Campus, Lister Hill Center, June 13-15, 2001. (Contact: Dr. Rosemary Yancik, GP, 301-496-5278)
Comparative Biology of Aging. BAP, GP, and NNA plan two exploratory workshops in this area. The first workshop is to be held in April 2001 and will involve a small group of investigators gathered to shape the major discussion issues and agenda for a larger workshop to be held in June 2001. The larger workshop will be convened to gather investigators using various aging models and investigators who can pose major issues of interest to human aging, to exchange information on the advantages and potential uses of the models for studies of aging, and to foster collaborations for mechanistic studies of the basic biology of aging in informative models. (Contacts: Dr. Jill Carrington, BAP, 301-496-6402; Dr. Evan Hadley, GP, 301435-3044; Dr. Brad Wise, NNA, 31-496-9350)
The initial meeting of the NIA Biospecimen Repository Oversight Committee is currently being organized to provide advice on the overall structure of the planned repository and to discuss the repository RFA. For additional information, contact Dr. Nadon. (Contact: Dr. Nancy Nadon, BAP, 301-496-6402)
Staging Reproductive Aging and Menopause (Exploratory Workshop). The NIA (Geriatrics Program and Biology of Aging Program) are cosponsoring this workshop with the National Institute of Child Health and Human Development, the Society for Reproductive Medicine, and the North American Menopause Society. The workshop will be convened in late spring or summer 2001. The overarching goal of this workshop is the identification of a logical division of (the last 10 to 15 years) hypothalamic-pituitary-ovarian function in women into stages that have research and clinical relevance. It is assumed the basis for these stages would be primarily clinical (e.g., menstrual cycle) and endocrinologic (e.g., follicle stimulating hormone [FSH], etc.) changes that occur as a normal woman progresses through her later years of reproductive function prior to culmination at menopause. Other factors could be taken into account such as vasomotor symptoms, duration or intensity of menstrual flow, etc. (Contacts: Dr. Sherry Sherman, GP, 301-435-3048; Dr. Frank Bellino, BAP, 301-496-4996)
The NIA Aging and Genetic Epidemiology Working Group commentary, "Genetic Epidemiologic Studies on Age-specified Traits" was recently published in the American Journal of Epidemiology (Am J Epidemiol 2000; 152 (11): 1003-8). This commentary calls attention to the value of combining genetic and epidemiologic methods in studies to understand the determinants of two crucial aspects of aging: ages at which certain outcomes (e.g., disease, mortality) occur and rates of change with age of individual's characteristics (e.g., physiologic functions, disease risk factors). This commentary is based on a report prepared by the Aging and Genetic Epidemiology Working Group, convened by the National Institute on Aging to review opportunities for research on the genetic epidemiology of age-related outcomes. The report, which contains more extensive discussion, literature review, and references, is available at http://www.nia.nih.gov/ResearchInformation/ConferencesAndMeetings/AgingEpidemiology.htm.
ADEAR Center Packaged Searches in Three New Electronic Formats The ADEAR Center's CHID (Combined Health Information Database) page www.alzheimers.org/chid.html , on its Web site www.alzheimers.org, now includes reading lists for family and professional caregivers in PDF format. Links are provided to Adobe Acrobat and a companion program that converts PDF files to HTML for use with screen readers and voice recognition software. Automated CHID searches have been added listing the most relevant and up-to-date materials on a variety of AD topics. The reading lists and CHID searches are designed to meet the needs of all end-users and comply with section 508 of the Rehabilitation Act Amendment of 1998 which requires that electronic and information technology be developed, procured, maintained, or used by the Federal Government be accessible to people with disabilities.
NIA Alzheimer's Disease Clinical Trials Database Now Available Through National Library of Medicine (NLM) NIA's Alzheimer's Disease Clinical Trials Database (ADCTD) of studies on AD and dementia was launched in 1999. In collaboration with NLM, all of the studies from the ADCTD have been posted on the NLM's site: http://clinicaltrials.gov. The site lists clinical trials conducted by NIH and other Federal agencies, the pharmaceutical industry, and nonprofit and private organizations.
NIA "Fit After 50" -- Exercise Book and Videotape Since September, over 18,000 exercise books have been distributed and over 6,000 videotapes sold. To date, nearly $43,000 has been generated in sales of the videotape. The exercise book was first published in 1998, from that point to the present over 352,940 books have been distributed and a total of 11,321 copies of the video have been sold. Quarterly press releases on the importance of exercise spurred newspapers, magazines, and websites to run articles. All cost recovery income helps defray the cost of the NIA Information Center contract.
Since the last NACA meeting, the following documents have been printed:
Age Page : Medicines -- Use Them Safely Age Page : Osteoporosis -- The Bone Thief Age Page : Skin Care and Aging
NIH has announced the appointment of Paul Sieving, M.D., Ph.D., as the new Director of the National Eye Institute (NEI) . Dr. Carl Kupfer, Director of the NEI since its inception, retired last year. Dr. Sieving is the Paul R. Lichter Professor of Ophthalmic Genetics and Professor of Ophthalmology and Visual Sciences at the W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan. He is also Director, Clinical Electrophysiology and Psychophysics Testing Service, and Director, Center for Retinal and Macular Degeneration. Dr. Sieving received his M.D. from the University of Illinois in 1978 and his Ph.D. in bioengineering at the University of Illinois (UI) in 1981. He completed a residency in ophthalmology at the Illinois Eye and Ear Infirmary, UI, Chicago. He also completed a postdoctoral research fellowship in physiology at the University of California - San Francisco. In 1985 he completed a fellowship in Retinal Dystrophies at the Massachusetts Eye and Ear Infirmary. Dr. Sieving will join NEI in the late spring.
From the NIH GUIDE - From Fall & Winter 2000-2001 Published since the last National Advisory Council on Aging Meeting. Also check our NIA website “ Funding Opportunities ” (Shown here are selected Notices relevant to NIA and selected Initiatives )
NoticeTo NIH Grantees/Contractors Regarding Letters or Notices From The Food and Drug Administration (FDA) http://grants.nih.gov/grants/guide/Notice-files/NOT-OD-00-053.html Release Date: September 22, 2000 Notice: OD-00-053 Announced by the National Institutes of Health Many NIH grantees/contractors conduct clinical research that involves a drug, biologic or device for which there is a Food and Drug Administration (FDA) Investigational New Drug Application (IND) and/or Investigational Device Exemption (IDE). When the NIH funds all, or part, of a clinical study that is being conducted under an IND and/or IDE, it is important that the NIH be knowledgeable about any significant communications with the FDA about that study. By statute, the FDA communicates with the sponsor of the IND or IDE. The sponsor may, or may not, be the NIH awardee institution or NIH-funded principal investigator. FDA regulation, 21 CFR 312.55, outlines the responsibilities of sponsors to keep each participating investigator informed during the course of the study. Thus this Notice to the awarding Institute(s) and Center(s) serves to complete the information loop. Awardee institutions must immediately notify the awarding Institute(s) and/or Center(s) of any of the following communications from the FDA regarding that research.
Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (PAR-00-037) http://grants.nih.gov/grants/guide/Notice-files/NOT-DE-01-001.html Release Date: October 25, 2000 Contact: Dr. Bradley C. Wise, (301) 496-9350 E-mail: bw86y@nih.gov Notice: DE-01-001 Announced with the National Institute of Child Health and Human Development, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Eye Institute, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, and the National Institute of Nursing Research. The purpose of this Notice is to provide additional information to prospective applicants for the Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (PAR-00-037) (http://grants.nih.gov/grants/guide/pa-files/PAR-00-037.html ). It is of special importance that institutions applying for this program provide a statement describing in the application the plan to consolidate neuroscience training positions from any existing predoctoral training grants that are supported by the NIH Institutes participating in this PA. All relevant, available training grants should be considered and some rationale presented if particular grants are not going to be included in the consolidation plan. The final application is to be submitted by May 10, 2001.
Approval Process for The Documentation of Compliance With NIH Guidelines on The Use of Human Pluripotent Stem Cells In NIH Research Proposed for Support Under Grants and Cooperative Agreements http://grants.nih.gov/grants/guide/Notice-files/NOT-OD-01-003.html Release Date: November 21, 2000 Notice: OD-01-003 (amended) Announced by the National Institutes of Health The only significant difference in this Notice and that published on October 16, 2000, is that there are separate descriptions of the materials to be submitted for human pluripotent stem cells derived from embryos or fetal tissue. The documentation to be submitted and the timetable for submission have not changed. However, a separate discussion of the process for embryos or fetal tissue clarifies the compliance approval process.
Announcement of Final PHS Policy on Instruction in the Responsible Conduct of Research http://grants.nih.gov/grants/guide/Notice-files/NOT-OD-01-007.html Release Date: December 5, 2000 Notice: OD-01-007 Announced by the Department of Health and Human Services The Office of Research Integrity (ORI) in collaboration with the Agency Research Integrity Liaison Officers for each of the Public Health Service (PHS) Operating Divisions, announced on July 17, 2000, (NIH Guide for Grants and Contracts, Notice OD-00-045) the availability for public comment of a Draft PHS Policy for Instruction in the Responsible Conduct of Research (RCR) for extramural institutions receiving PHS funds for research or research training. The comment period closed on September 21, 2000. In response to public comment, ORI and the PHS agencies have made substantial revisions to the draft policy and hereby announce the final "PHS Policy on Instruction in the Responsible Conduct of Research." The final policy, a summary of comments and revisions to the policy made in response thereto, a list of available resources for RCR education programs, and Frequently Asked Questions on the policy are located at (http://ori.hhs.gov) or may be obtained from ORI at 5515 Security Lane, Suite 700, Rockville, MD, 20852, Phone: 301-443-5300. Public comments on the draft policy are available for public inspection on ORI's premises from Monday-Friday between 9:00 a.m. and 5:00 p.m. Please call ORI for an appointment time.
Reminder on the Need for IACUC Approval Prior to Peer Review http://grants.nih.gov/grants/guide/Notice-files/NOT-OD-01-008.html Release Date: December 6, 2000 Notice: OD-01-008 Announced by the National Institutes of Health On May 1, 2000, the NIH announced that beginning with applications submitted for the January 2001 Council round, IRB approval is no longer required prior to NIH peer review of an application which involves human participants. (http://grants.nih.gov/grants/guide/Notice-files/NOT-OD-00-031.html ). This change in policy is intended to provide flexibility at the institutional level to reduce the workload burdens that many IRBs are currently facing, while still ensuring full protection of participants in human studies. At this time, however, there is no change in the NIH policy for submission of IACUC approval when animal studies are involved. IACUC approval is still required of all such applications either when the application is submitted, or within 60 days thereafter; otherwise, the application cannot be peer reviewed. Applicants are reminded that if IACUC approval does not accompany the application, they should wait until notified of the scientific review group assignment and then forward the documentation to the designated Scientific Review Administrator. Because of the different bases for IRB and IACUC review requirements, rulemaking would be required to allow similar flexibility for IACUC review. Over the next year, the NIH will closely monitor implementation of the revised policy on the timing of IRB approval. If as expected, this change in policy continues to provide the necessary safeguards but with enhanced institutional flexibility, the NIH will consider proceeding with rulemaking to permit similar flexibility in the timing of IACUC approvals.
2001 NIH Regional Seminars on Program Funding and Grants Administration -- March 15-16 and June 7-8, 2001 http://grants.nih.gov/grants/guide/Notice-files/NOT-OD-01-010.html Release Date: December 14, 2000 Notice: OD-01-010 Announced by the National Institutes of Health Two regional seminars covering topics related to the National Institutes of Health extramural program funding and grants administration have been scheduled for 2001. The first will be held March 15 and 16 in Houston, Texas, co-hosted by the University of Texas MD Anderson Cancer Center, University of Texas Houston Health Science Center and University of Texas Galveston Medical Branch. The second seminar will be offered June 7 and 8 in Portland, Oregon, hosted by Oregon Health Sciences University.
Implementation of Policies for Human Intervention Studies http://grants.nih.gov/grants/guide/Notice-files/NOT-AG-01-001.html Release Date: December 20, 2000 Contact: Dr. Miriam F. Kelty, (301) 496-9322 E-mail: mk46u@NIH.GOV Notice: AG-01-001 The National Institute on Aging has revised and updated its December 10, 1999 publication “Implementation of Policies for Human Intervention Studies”. This updated policy includes guidelines and requirements for Phase I, Phase II, Phase III clinical trials and can be obtained from http://www.nih.gov/funding/policy/humint.htm. All applications assigned to NIA that propose such interventions must comply with that policy and with the corresponding NIH policy on ”Data and Safety Monitoring”, available from http://grants.nih.gov/grants/guide/Notice-files/not98-084.html.
National Research Service Award (NRSA) Stipend Increase and Other Budgetary Changes Effective for Fiscal Year 2001 http://grants.nih.gov/grants/guide/Notice-files/NOT-OD-01-011.html Release Date: January 8, 2001 Notice: OD-01-011 Announced by the National Institutes of Health, Agency for Healthcare Research and Quality, and the Health Resources Services Administration. The budgetary changes described below for Fiscal Year 2001 NRSA awards affect the stipend levels for predoctoral and postdoctoral trainees and fellows. In addition, the training related expenses for postdoctoral trainees and the institutional allowance for postdoctoral fellows are being increased. It Should Be Noted that the Described Budgetary Changes Are Effective Only for Nrsa Awards Made With FY 2001 Funds. Retroactive adjustments or supplementation of stipends or other budgetary categories with NRSA funds for an award made prior to October 1, 2000 is not permitted. Budgetary adjustments for training grant and fellowship awards, therefore, will be made only at the time of the FY 2001 award. Adjustments of stipends and other benefits for trainees will be made only at the time of appointment or reappointment to training grants made with FY 2001 funds.
Format of Grant and Cooperative Agreement Applications Submitted to NIH http://grants.nih.gov/grants/guide/Notice-files/NOT-OD-01-012.html Release Date: January 8, 2001 Notice: OD-01-012 Announced by the National Institutes of Health The main goal of the NIH is to identify and support the best possible biomedical and behavioral research in order to improve the health of all Americans. The scale of the effort (over 46,000 competing applications received in fiscal year 2000) requires standards for application submission. These specifications allow all applicants comparable space and provide reviewers with applications that are easyto read, thus allowing them to concentrate on the scientific evaluation of the proposed research. The specific format instructions are: PHS 398: http://grants.nih.gov/grants/funding/phs398/section_1.html#general PHS 416: http://grants.nih.gov/grants/funding/416/section_1.htm#general Phase I SBIR and STTR: http://grants.nih.gov/grants/funding/sbirsttr1/Apdx%20A%20-%20Instruct.pdf Phase II SBIR and STTR: http://grants.nih.gov/grants/funding/sbir2/intro.htm#prep.
Salary Limitation on Grants, Cooperative Agreements and Contracts http://grants.nih.gov/grants/guide/Notice-files/NOT-OD-01-013.html Release Date: January 11, 2001 Notice: OD-01-013 Announced by the National Institutes of Health The purpose of this Notice is to provide updated information regarding the salary limitation as it relates to NIH grant and cooperative agreement awards. This information also applies to extramural research and development contract awards. The last Notice in the NIH Guide for Grants and Contracts regarding the salary limitation was published January 6, 2000. Fiscal Year (FY) 2001 is the twelfth consecutive year for which there is a legislatively mandated provision for the limitation of salary. Specifically, the Department of Health and Human Services (HHS) Appropriation Act for FY 2001, Public Law 106-554, restricts the amount of direct salary of an individual under an NIH grant or cooperative agreement (hereafter referred to as a grant) or applicable contract to Executive Level I of the Federal Executive Pay scale. The Executive Level I annual salary rate is $157,000 for the period October 1 through December 31, 2000. Effective January 1, 2001, the Executive Level I salary level increased to $161,200.
Notice of Legislative Mandates Contained in The Fy2001 Omnibus Appropriations P.L. 106-554; Signed December 21, 2000 http://grants.nih.gov/grants/guide/Notice-files/NOT-OD-01-014.html Release Date: January 18, 2001 Notice: OD-01-014 Announced by the National Institutes of Health The purpose of this Notice is to provide information on the following statutory provisions that limit the use of funds on National Institutes of Health (NIH) grant, cooperative agreement, and contract awards:
Exploratory Studies of Sustained Caloric Restriction in Non-Obese Persons: Physiologic Effects and Comparisons/Interactions With Physical Activity http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-01-001.html Release Date: October 12, 2000 Contact: Dr. Chhanda Dutta, (301) 435-3048 E-mail: cd23z@nih.gov RFA: AG-01-001 Application Receipt Date: April 25, 2001 The purpose of this RFA is to solicit applications for cooperative agreements (U01s) for exploratory controlled human intervention studies on the effects of caloric restriction (CR) interventions on physiology, body composition, and risk factors for age-related pathologies in non-obese persons. Applications are also invited for studies of similarities, differences and/or potential interactions between the effects of CR and of physical activity (PA) on these outcomes. Studies in young adults and/or middle-aged persons up to age 60 may be proposed.
Vaccine and Immune Therapy For Alzheimer's Disease http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-01-003.html Release Date: December 6, 2000 Contact: Dr. D. Stephen Snyder, (301) 496-9350 E-mail: ss82f@nih.gov RFA: AG-01-003 Application Receipt Date: February 20, 2001 Announced with the National Institute of Neurological Disorders and Stroke ( http://www.ninds.nih.gov/ ) The purpose of this RFA is to solicit applications for individual research grant application (R01) mechanisms to study the immunological processes in Alzheimer's disease. It has been estimated that as many as four million Americans currently suffer from Alzheimer's disease, and failure to successfully prevent and treat the disease will result in more than a tripling of its prevalence - from four to fourteen million - over the next 50 years. Based on recent findings it is apparent that there is a pressing need to understand the immunological processes involved that appear to limit the deposition of amyloid or enhance its removal from brain; to determine whether a similar approach may be useful for removal of NFT; and to determine which process, if any, prevents the related cognitive decline.
NIA Pilot Research Grant Program http://grants.nih.gov/grants/guide/pa-files/PA-01-037.html Release Date: December 20, 2000 Contacts: Dr. David B. Finkelstein, Biology of Aging Program, (301) 496-6402, BAPquery@exmur.nia.nih.gov Ms. Angie Chon-Lee, Behavioral and Social Research Program, (301) 594-5943, BSRquery@exmur.nia.nih.gov Dr. Judy Finkelstein, Neuroscience and Neuropsychology of Aging Program, (301) 496-9350, NNAquery@exmur.nia.nih.gov Ms. Wanda Solomon, Geriatrics Program, (301) 435-3046, GPquery@exmur.nia.nih.gov PA NUMBER: PA-01-037 Application Receipt Dates: March 20, 2001; July 17, 2001; November 16, 2001 The purpose of this Program Announcement is to solicit small grant (R03) applications in specific areas to: (1) stimulate and facilitate the entry of promising new investigators into aging research, and (2) encourage established investigators to enter new targeted, high priority areas in this research field. This Small Grant (R03) Program provides support for pilot research that is likely to lead to a subsequent individual research project grant (R01) that is focused on aging and/or a significant advancement of aging research.
Planning Grants for HIV/AIDS Prevention and Treatment Intervention in Middle-Aged and Older Populations http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-01-004.html Release Date: January 8, 2001 Contact: Dr. Marcia Ory, (301) 402-4156 E-mail: mo12x@NIH.GOV RFA: AG-01-004 Application Receipt Date: March 26, 2001 Announced with the National Institute on Mental Health ( http://www.nimh.nih.gov/ ) This purpose of this RFA is to solicit applications for planning grants (R21) to assist in the design, testing and preliminary evaluation of prevention and treatment interventions for HIV/AIDS in the middle-aged and older population. Effective strategies for AIDS prevention and treatment through behavior change interventions for the major populations at risk have been identified but not yet applied to the fifty plus population.
Age-Related Changes in Reading and Oral Language Comprehension http://grants.nih.gov/grants/guide/pa-files/PA-01-002.html Release Date: October 25, 2000 Contacts: Dr. Daniel B. Berch, Behavioral and Social Research Program, (301) 496-3137, db254g@NIH.GOV Dr. Judith A. Finkelstein, Neuroscience and Neuropsychology of Aging Program, (301) 496-9350, jf119k@nih.gov PA NUMBER: PA-01-002 Announced with National Institute of Child Health and Human Development (http://www.nichd.nih.gov) The purpose of this PA is to solicit applications for research projects designed to examine age-related changes in reading and language comprehension abilities and to develop interventions that prevent or compensate for declines. Late adulthood is associated with changes, generally declining, in the communicative abilities important for reading and language comprehension. Evidence suggests that factors associated with the development of reading and oral language comprehension skills (e.g., the age of acquisition, the proficiency attained in early life, diagnoses of learning disabilities and subsequent interventions) and ongoing experiences (e.g., education, occupation, leisure activities, social interaction) influence the skill levels attained during adulthood.
Planning Grant for Clinical Research Training in Minority Institutions http://grants.nih.gov/grants/guide/rfa-files/RFA-AR-00-009.html Release Date: September 26, 2000 Contact: Dr. Sidney M. Stahl, (301) 402-4156 E-mail: ss333h@NIH.GOV RFA: AR-00-009 Application Receipt Date: December 19, 2000 Announced with the Office of Research on Minority Health, National Cancer Institute, National Center for Research Resources, National Center for Complementary and Alternative Medicine, National Eye Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Drug Abuse, and the National Institute of Nursing Research. The purpose of this RFA is to invite Minority Institutions with professional schools in one or more of the health care disciplines to apply for a planning grant to develop a Master of Clinical Research or a Master of Public Health in a clinically relevant area. This request is intended to stimulate the inclusion of high-quality, multidisciplinary didactic training as part of the career development of clinical investigators being trained in Minority institutions. The planning grant supports the initial assessment needed to begin development and/or improvement of core courses designed as in-depth instruction in the fundamental skills, methodology, theories, and conceptualizations necessary for the well-trained, independent, clinical investigator.
Studies of Sensory-Motor Functions Responsive to Gravity in Genetically Altered Model Systems http://grants.nih.gov/grants/guide/rfa-files/RFA-DC-01-001.html Release Date: October 16, 2000 Contact: Dr. Judith A. Finkelstein, (301) 496-9350 E-mail: jf119k@nih.gov RFA: DC-01-001 Application Receipt Date: January 17, 2001 Announced with the National Institute on Deafness and Other Communication Disorders ( http://www.nidcd.nih.gov/ ), and the National Aeronautics and Space Administration ( http://www.nasa.gov/ ) The purpose of this RFA is to solicit applications to stimulate research utilizing specific, well-characterized transgenic and mutant animal models to elucidate molecular bases for the normal development and function of sensory-motor mechanisms that detect and respond to gravity. Gravitational loading plays an important role in the development (maturation and aging) of the body's gravity-sensing organs, notably the vestibular receptors, the proprioceptors, the central motor pathways and the skeletal muscles. These functions are fundamental to an organism's ability to control its balance and posture, locomotion and other volitional movements, and its spatial orientation. A deeper understanding of the interactions between gravity and mechanisms of gene expression in sensory-motor functions would impact the fields of developmental biology, vestibular and motor physiology, space biology and space medicine.
Application Receipt Date: Applications will be accepted MONTHLY on the 9th of each month. Announced with the National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute of Neurological Disorders and Stroke. The purpose of this RFA is to solicit applications for investigator-initiated research applications for mechanistic studies in clinical trials of immunomodulatory interventions for immune system mediated diseases, including, but not limited to, asthma and allergy, graft failure in solid organ, tissue, cell and stem cell transplantation, and autoimmune diseases. Specifically, this Request for Applications (RFA) is a continuation and modification of RFA AI-00-005. It focuses on the inclusion of patients and utilization of patient samples for the valuation of immunologic and other relevant parameters to facilitate the study and definition of immunological mechanisms underlying the intervention, the mechanisms of disease pathogenesis, surrogate/biomarkers markers of disease activity and therapeutic effect, and mechanisms of human immunologic function. The parent or core clinical trial must have independent financial support and will NOT receive support under this RFA. Proposed mechanistic studies associated with clinical trials supported by industry are particularly encouraged but clinical trials supported by any source, public or private, are eligible.
Application Receipt Date: Applications will be accepted MONTHLY on the 9th of each month.
Announced with the National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute of Neurological Disorders and Stroke.
The purpose of this RFA is to solicit applications for investigator-initiated research applications for mechanistic studies in clinical trials of immunomodulatory interventions for immune system mediated diseases, including, but not limited to, asthma and allergy, graft failure in solid organ, tissue, cell and stem cell transplantation, and autoimmune diseases. Specifically, this Request for Applications (RFA) is a continuation and modification of RFA AI-00-005. It focuses on the inclusion of patients and utilization of patient samples for the valuation of immunologic and other relevant parameters to facilitate the study and definition of immunological mechanisms underlying the intervention, the mechanisms of disease pathogenesis, surrogate/biomarkers markers of disease activity and therapeutic effect, and mechanisms of human immunologic function. The parent or core clinical trial must have independent financial support and will NOT receive support under this RFA. Proposed mechanistic studies associated with clinical trials supported by industry are particularly encouraged but clinical trials supported by any source, public or private, are eligible.
Application Receipt Dates: February 16, 2001 and August 14, 2001 Announced with the National Cancer Institute, National Eye Institute, National Heart, Lung, and Blood Institute, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, and the National Library of Medicine. The purpose of this PA is to invite applications for R01 awards to support Bioengineering Research Partnerships (BRPs) for basic multidisciplinary research addressing important biological or medical research problems. A BRP is a multidisciplinary research team applying an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. The partnership must include appropriate bioengineering expertise in combination with basic and/or clinical investigators. A BRP may propose discovery-driven, developmental, non-hypothesis-driven, design-directed, or hypothesis-driven research at universities, national laboratories, medical schools, large or small businesses, or other public and private entities.
Application Receipt Dates: February 16, 2001 and August 14, 2001
Announced with the National Cancer Institute, National Eye Institute, National Heart, Lung, and Blood Institute, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, and the National Library of Medicine.
The purpose of this PA is to invite applications for R01 awards to support Bioengineering Research Partnerships (BRPs) for basic multidisciplinary research addressing important biological or medical research problems. A BRP is a multidisciplinary research team applying an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. The partnership must include appropriate bioengineering expertise in combination with basic and/or clinical investigators. A BRP may propose discovery-driven, developmental, non-hypothesis-driven, design-directed, or hypothesis-driven research at universities, national laboratories, medical schools, large or small businesses, or other public and private entities.
Application Receipt Date: March 14, 2001 Announced with National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (http://www.nih.gov/niams/), and the National Institute of Child Health and Human Development (NICHD) (http://www.nichd.nih.gov/). The purpose of this RFA is to stimulate and support new research projects that have the potential to increase our understanding of skeletal pathology in osteogenesis imperfecta (OI), and to lead to improved therapeutic approaches to the disease. In particular, it is intended that new studies should test the importance of dysregulated bone remodeling in the pathogenesis of OI, with a view to exploiting pharmacological therapies that may ameliorate the consequences of the underlying genetic defects. A second major goal is an improved understanding of osteoprogenitor cell biology that will form the basis for future therapeutic efforts employing genetic modification and transplantation of such cells.
Application Receipt Date: March 14, 2001
Announced with National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (http://www.nih.gov/niams/), and the National Institute of Child Health and Human Development (NICHD) (http://www.nichd.nih.gov/).
The purpose of this RFA is to stimulate and support new research projects that have the potential to increase our understanding of skeletal pathology in osteogenesis imperfecta (OI), and to lead to improved therapeutic approaches to the disease. In particular, it is intended that new studies should test the importance of dysregulated bone remodeling in the pathogenesis of OI, with a view to exploiting pharmacological therapies that may ameliorate the consequences of the underlying genetic defects. A second major goal is an improved understanding of osteoprogenitor cell biology that will form the basis for future therapeutic efforts employing genetic modification and transplantation of such cells.
Application Receipt Date: April 11, 2001 Announced with the National Institute on Drug Abuse (http://www.nida.nih.gov), National Institute of Mental Health (http://www.nimh.nih.gov), National Institute of Dental and Craniofacial Research (http://www.nidcr.nih.gov), National Eye Institute (http://www.nei.nih.gov), National Institute on Deafness and Other Communication Disorders (http://www.nidcd.nih.gov), National Human Genome Research Institute (http://www.nhgri.nih.gov), National Institute of Diabetes and Digestive and Kidney Diseases (http://www.niddk.nih.gov), National Institute of Arthritis and Musculoskeletal and Skin Diseases (http://www.nih.gov/niams), National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov), and the National Institute of Neurological Disorders and Stroke (http://www.ninds.nih.gov). This RFA solicits proposals for development of tools and techniques for the establishment of random and targeted sequence-tagged insertion libraries of embryonic stem (ES) cells that can be used to generate mutant mice in which the expression of the tagged gene could be controlled temporally and spatially. The development of such a resource for wide distribution to the scientific community would make it possible to scan the sequence database for any gene of interest and order the corresponding targeted ES cell line. Ideally, the insertional mutagenesis system developed would permit a wide range of genetic analyses and manipulations, including enhancer-trapping, conditional knockouts, conditional expression or overexpression, etc. It also would permit the larger community of investigators to utilize genomic resources efficiently. This effort complements ongoing National Institutes of Health (NIH) efforts to create and characterize induced point mutations in mice using ethylnitrosourea (ENU) and provides a functional genomics tool to translate the information from the Mouse Genome Sequencing Project. Further information about NIH initiatives on mouse genomics and genetics resources is available at http://www.nih.gov/science/mouse. This initiative will utilize the research project grant (R01) and exploratory/development grant (R21) mechanisms. It will be run in parallel with a program of identical scientific scope that uses the Small Business Innovation Research/Small Business Technology Transfer Research (SBIR/STTR) programs (http://grants.nih.gov/grants/funding/sbirsttr1/index.pdf).
Application Receipt Date: April 11, 2001
Announced with the National Institute on Drug Abuse (http://www.nida.nih.gov), National Institute of Mental Health (http://www.nimh.nih.gov), National Institute of Dental and Craniofacial Research (http://www.nidcr.nih.gov), National Eye Institute (http://www.nei.nih.gov), National Institute on Deafness and Other Communication Disorders (http://www.nidcd.nih.gov), National Human Genome Research Institute (http://www.nhgri.nih.gov), National Institute of Diabetes and Digestive and Kidney Diseases (http://www.niddk.nih.gov), National Institute of Arthritis and Musculoskeletal and Skin Diseases (http://www.nih.gov/niams), National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov), and the National Institute of Neurological Disorders and Stroke (http://www.ninds.nih.gov).
This RFA solicits proposals for development of tools and techniques for the establishment of random and targeted sequence-tagged insertion libraries of embryonic stem (ES) cells that can be used to generate mutant mice in which the expression of the tagged gene could be controlled temporally and spatially. The development of such a resource for wide distribution to the scientific community would make it possible to scan the sequence database for any gene of interest and order the corresponding targeted ES cell line. Ideally, the insertional mutagenesis system developed would permit a wide range of genetic analyses and manipulations, including enhancer-trapping, conditional knockouts, conditional expression or overexpression, etc. It also would permit the larger community of investigators to utilize genomic resources efficiently. This effort complements ongoing National Institutes of Health (NIH) efforts to create and characterize induced point mutations in mice using ethylnitrosourea (ENU) and provides a functional genomics tool to translate the information from the Mouse Genome Sequencing Project. Further information about NIH initiatives on mouse genomics and genetics resources is available at http://www.nih.gov/science/mouse. This initiative will utilize the research project grant (R01) and exploratory/development grant (R21) mechanisms. It will be run in parallel with a program of identical scientific scope that uses the Small Business Innovation Research/Small Business Technology Transfer Research (SBIR/STTR) programs (http://grants.nih.gov/grants/funding/sbirsttr1/index.pdf).
Application Receipt Date: April 11, 2001 Announced with the National Institute on Drug Abuse (http://www.nida.nih.gov), National Institute on Dental and Craniofacial Research (http://www.nidcr.nih.gov), National Institute on General Medical Sciences (http://www.nigms.nih.gov), National Institute of Mental Health (http://www.nimh.nih.gov), National Eye Institute (http://www.nei.nih.gov), National Institute on Deafness and Other Communication Disorders (http://www.nidcd.nih.gov), National Human Genome Research Institute (http://www.nhgri.nih.gov), National Center for Research Resources (http://www.ncrr.nih.gov), National Institute of Diabetes and Digestive and Kidney Diseases (http://www.niddk.nih.gov), National Institute on Alcohol Abuse and Alcoholism (http://www.niaaa.nih.gov), National Institute of Child Health and Human Development (http://www.nichd.nih.gov), National Institute of Environmental Health Sciences (http://www.niehs.nih.gov), National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov), and the National Institute of Neurological Disorders and Stroke (http://www.ninds.nih.gov). This Request for Applications (RFA) solicits proposals for development of tools and techniques for the establishment of random and targeted sequence-tagged insertion libraries of embryonic stem (ES) cells that can be used to generate mutant mice in which the expression of the tagged gene could be controlled temporally and spatially. The development of such a resource for wide distribution to the scientific community would make it possible to scan the sequence database for any gene of interest and order the corresponding targeted ES cell line. Ideally, the insertional mutagenesis system developed would permit a wide range of genetic analyses and manipulations, including overexpression, etc. It also would permit the larger community of investigators to utilize genomic resources efficiently. This effort complements ongoing National Institutes of Health (NIH) efforts to create and characterize induced point mutations in mice using ethylnitrosourea (ENU) and provides a functional genomics tool to translate the information from the Mouse Genome Sequencing Project. Further information about NIH initiatives on mouse genomics and genetics resources is available at http://www.nih.gov/science/mouse. Because this initiative deals with the development of technology-driven commercial products, this initiative will use the Small Business Innovation Research/Small Business Technology Transfer Research (SBIR/STTR) programs. This RFA provides a flexible system within the SBIR/STTR programs to cover the research steps needed to develop and validate technology to generate insertional mutations in mouse ES cells. It will be run in parallel with a program of identical scientific scope utilizing the research project grant (R01) and for exploratory/development grant (R21) (see http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-01-011.html ) mechanisms.
Announced with the National Institute on Drug Abuse (http://www.nida.nih.gov), National Institute on Dental and Craniofacial Research (http://www.nidcr.nih.gov), National Institute on General Medical Sciences (http://www.nigms.nih.gov), National Institute of Mental Health (http://www.nimh.nih.gov), National Eye Institute (http://www.nei.nih.gov), National Institute on Deafness and Other Communication Disorders (http://www.nidcd.nih.gov), National Human Genome Research Institute (http://www.nhgri.nih.gov), National Center for Research Resources (http://www.ncrr.nih.gov), National Institute of Diabetes and Digestive and Kidney Diseases (http://www.niddk.nih.gov), National Institute on Alcohol Abuse and Alcoholism (http://www.niaaa.nih.gov), National Institute of Child Health and Human Development (http://www.nichd.nih.gov), National Institute of Environmental Health Sciences (http://www.niehs.nih.gov), National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov), and the National Institute of Neurological Disorders and Stroke (http://www.ninds.nih.gov).
This Request for Applications (RFA) solicits proposals for development of tools and techniques for the establishment of random and targeted sequence-tagged insertion libraries of embryonic stem (ES) cells that can be used to generate mutant mice in which the expression of the tagged gene could be controlled temporally and spatially. The development of such a resource for wide distribution to the scientific community would make it possible to scan the sequence database for any gene of interest and order the corresponding targeted ES cell line. Ideally, the insertional mutagenesis system developed would permit a wide range of genetic analyses and manipulations, including overexpression, etc. It also would permit the larger community of investigators to utilize genomic resources efficiently. This effort complements ongoing National Institutes of Health (NIH) efforts to create and characterize induced point mutations in mice using ethylnitrosourea (ENU) and provides a functional genomics tool to translate the information from the Mouse Genome Sequencing Project. Further information about NIH initiatives on mouse genomics and genetics resources is available at http://www.nih.gov/science/mouse. Because this initiative deals with the development of technology-driven commercial products, this initiative will use the Small Business Innovation Research/Small Business Technology Transfer Research (SBIR/STTR) programs. This RFA provides a flexible system within the SBIR/STTR programs to cover the research steps needed to develop and validate technology to generate insertional mutations in mouse ES cells. It will be run in parallel with a program of identical scientific scope utilizing the research project grant (R01) and for exploratory/development grant (R21) (see http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-01-011.html ) mechanisms.
Announced with the National Human Genome Research Institute, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, and the National Institute of Mental Health. The purpose of this Small Grant (R03) Program Announcement (PA) is designed to solicit small research projects that anticipate, analyze, and address the ethical, legal, and social implications (ELSI) of the discovery of new genetic technologies and the availability and use of genetic information resulting from human genetics and genomic research. Of particular interest are studies that: 1) examine the issues surrounding the completion of the human DNA sequence and the study of human genetic variation; 2) examine the issues raised by the integration of genetic technologies and information into health care and public health activities; 3) examine the issues raised by the integration of knowledge about genomics and gene-environment interactions into non-clinical settings; 4) explore the ways in which new genetic knowledge may interact with a variety of philosophical, theological, and ethical perspectives; and 5) explore how socioeconomic factors, gender, and concepts of race, ethnicity and culture influence the use and interpretation of genetic information, the utilization of genetic services, and the development of policy.
Announced with the National Human Genome Research Institute, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, and the National Institute of Mental Health.
The purpose of this Small Grant (R03) Program Announcement (PA) is designed to solicit small research projects that anticipate, analyze, and address the ethical, legal, and social implications (ELSI) of the discovery of new genetic technologies and the availability and use of genetic information resulting from human genetics and genomic research. Of particular interest are studies that: 1) examine the issues surrounding the completion of the human DNA sequence and the study of human genetic variation; 2) examine the issues raised by the integration of genetic technologies and information into health care and public health activities; 3) examine the issues raised by the integration of knowledge about genomics and gene-environment interactions into non-clinical settings; 4) explore the ways in which new genetic knowledge may interact with a variety of philosophical, theological, and ethical perspectives; and 5) explore how socioeconomic factors, gender, and concepts of race, ethnicity and culture influence the use and interpretation of genetic information, the utilization of genetic services, and the development of policy.
Announced with the National Human Genome Research Institute, National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Environmental Health Sciences, National Institute for General Medical Sciences National Institute of Mental Health, National Institute of Nursing Research, and the National Institute of Neurological Disorders and Stroke. The purpose of this Program Announcement (PA) is to solicit research projects that anticipate, analyze, and address the ethical, legal, and social implications of the discovery of new genetic technologies and the availability and use of genetic information resulting from human genetics and genomic research. Of particular interest are studies that: 1) examine the issues surrounding the completion of the human DNA sequence and the study of human genetic variation; 2) examine the issues raised by the integration of genetic technologies and information into health care and public health activities; 3) examine the issues raised by the integration of knowledge about genomics and gene-environment interactions into non-clinical settings; 4) explore the ways in which new genetic knowledge may interact with a variety of philosophical, theological, and ethical perspectives; and 5) explore how socioeconomic factors, gender, and concepts of race, ethnicity and culture influence the use and interpretation of genetic information, the utilization of genetic services, and the development of policy.
Announced with the National Human Genome Research Institute, National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Environmental Health Sciences, National Institute for General Medical Sciences National Institute of Mental Health, National Institute of Nursing Research, and the National Institute of Neurological Disorders and Stroke.
The purpose of this Program Announcement (PA) is to solicit research projects that anticipate, analyze, and address the ethical, legal, and social implications of the discovery of new genetic technologies and the availability and use of genetic information resulting from human genetics and genomic research. Of particular interest are studies that: 1) examine the issues surrounding the completion of the human DNA sequence and the study of human genetic variation; 2) examine the issues raised by the integration of genetic technologies and information into health care and public health activities; 3) examine the issues raised by the integration of knowledge about genomics and gene-environment interactions into non-clinical settings; 4) explore the ways in which new genetic knowledge may interact with a variety of philosophical, theological, and ethical perspectives; and 5) explore how socioeconomic factors, gender, and concepts of race, ethnicity and culture influence the use and interpretation of genetic information, the utilization of genetic services, and the development of policy.
Announced with the National Cancer Institute, National Heart, Lung, and Blood Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Child Health and Human Development, National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute of Nursing Research. The purpose of this Program Announcement is to invite applications from investigators for research studies that will address the relationship between physical activity and obesity. Three general areas of research are encouraged: (1) studies (including observational and prospective) examining physical activity and obesity relationships; (2) studies to improve methodology of assessment of physical activity and energy balance; and (3) studies to test intervention approaches that incorporate physical activity for obesity prevention or treatment related to chronic diseases.
Announced with the National Cancer Institute, National Heart, Lung, and Blood Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Child Health and Human Development, National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute of Nursing Research.
The purpose of this Program Announcement is to invite applications from investigators for research studies that will address the relationship between physical activity and obesity. Three general areas of research are encouraged: (1) studies (including observational and prospective) examining physical activity and obesity relationships; (2) studies to improve methodology of assessment of physical activity and energy balance; and (3) studies to test intervention approaches that incorporate physical activity for obesity prevention or treatment related to chronic diseases.
Date: 01/12/01
| Disclaimer | Accessibility | Privacy Policy | Contact Us | Site Map
